Request Sample
Request Methodology
Description
Chronic Idiopathic Constipation (CIC) Treatment Market size was valued at USD 8.2 billion in 2021 and is expected to grow at a CAGR of 7.2% during the forecast period 2022-2028. Chronic idiopathic constipation is a functional gastrointestinal disorder which leads to difficulty in defecating. It is a more chronic or severe condition and the symptoms of the disease include bloating, abdominal discomfort, hard stool, incomplete evacuation, gastric pain, and strain during the bowel movement. It is an idiopathic condition due to the causes of the disease are unclear, however, it may cause due to psychological, neurological, and psychosomatic conditions. Chronic idiopathic constipation is majorly caused in the adults or geriatric people. Diagnosis of CIC is difficult due to the lack of physiological causes and physicians look for symptoms like weight, blood in stool, and low blood count among others. The chronic idiopathic constipation Treatment market is growing at a significant CAGR owing to recent product approvals and competitors focus on the development of newer drugs for CIC treatment. Moreover, increase in the prevalence of chronic idiopathic constipation cases also expected to propel the market revenue over the forecast period. Acquisitions and mergers, product approvals, and product launchings are the key strategies adopted by the companies for increasing their revenue share in the market.
Key Developments:
In September 2017, Astellas Pharma, Inc. submitted the Supplemental new drug application for Linaclotide for patients with chronic idiopathic constipation in Japan
